Abeona Therapeutics (ABEO) Total Non-Current Liabilities (2011 - 2026)

Abeona Therapeutics' Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $40.0 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 20.6% year-over-year to $40.0 million; the TTM figure through Mar 2026 stood at $40.0 million (up 20.6% YoY), while the FY2025 annual figure was $41.5 million, up 26.05% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $40.0 million, down from $41.5 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $73.7 million in Q3 2024, with the low at $16.9 million in Q3 2023.
• The 5-year median for Total Non-Current Liabilities is $32.9 million (2024), against an average of $31.9 million.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities soared 335.51% in 2024, then slumped 49.41% in 2025.
• Abeona Therapeutics' Total Non-Current Liabilities stood at $17.8 million in 2022, then grew by 0.16% to $17.8 million in 2023, then soared by 84.5% to $32.9 million in 2024, then grew by 26.05% to $41.5 million in 2025, then decreased by 3.41% to $40.0 million in 2026.
• Business Quant data shows ABEO's Total Non-Current Liabilities at $40.0 million in Q1 2026, $41.5 million in Q4 2025, and $37.3 million in Q3 2025.